Edited by Paolo A. Ascierto, Carlo Bifulco, Sandra Demaria, Reinhard Dummer, Patrick Hwu, Francesco Marincola, Giuseppe Masucci, Iman Osman, Igor Puzanov.
Volume 19 Supplement 1
Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts
Meeting abstracts
Publication of this supplement has not been supported by sponsorship. Some Supplement Editors declare potential competing interest, as follow: Paolo A. Ascierto (Consulting fee: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore - Contracted Research: BMS, Roche, Array - Travel support: MSD) - Carlo Bifulco (Consultant/advisory relationship: PrimeVax, BMS, Ventana, HalioDx; Stock Ownership: PrimeVax; Patent US20180322632A1: Image processing systems and methods for displaying multiple images of a biological specimen) - Sandra Demaria (grant to Institution from Lytix Biopharma and Nanobiotix, honorarium for advisory/consulting from Lytix Biopharma, Ono Pharmaceutical, and EMD Serono) - Patrick Hwu (Scientific Advisory Board: Immatics, Dragonfly) - Igor Puzanov (consulting: Amgen, Merck, Iovance).
Virtual2-5 December 2020
-
Citation: Journal of Translational Medicine 2021 19(Suppl 1):110
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 6.2
Source Normalized Impact per Paper (SNIP): 1.234
SCImago Journal Rank (SJR): 1.611Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 86Usage 2023
Downloads: 4,999,990
Altmetric mentions: 8,678